PIPELINE
  • ONGOING PROJECTS
OUR PIPELINE

Currently, more than ten novel therapeutic monoclonal antibodies, antibody-drug conjugates (ADCs) and bispecific antibody drugs are being developed for advanced cancers (I/O, tumor specific antigen [TSA] or tumor associated antigen [TAA] targets), ophthalmic, and respiratory diseases. The HER2-ADC project is now in phase I clinical trials, currently open to patient recruitment at MD Anderson Cancer Center TX and Memorial Sloan-Kettering Cancer Center NY.

图片.png

  • PROGRAM

    PROGRESS

  • Target

    Indication

    Discovery Pre-clinical Phase I Phase II Phase III

  • ADC

  • HER2

    Breast Cancer

    Phase I
    Mechanism:
    Targetting HER2, with proprietary ADC technology

    Indication:
    HER2 positive solid tumor

    Date commenced phase:
    May 2018

    IND Filing:
    US: March 2018
    China: July 2017
  • Undisclosed

    Triple Negative Breast Cancer

    Preclinical
    Mechanism
    Proprietaty ADC technology

    Indication:
    Triple Negative Breast Cancer

    Date commenced phase:
    Q3 2018

    Estimated filing:
    US: June 2019
    China:
  • Undisclosed

    Gastric Cancer

    Preclinical
    Mechanism:
    Proprietaty ADC technology

    Indication:
    Gastric Cancer

    Date commenced phase:
    Q2 2018

    Estimated filing:
    December 2019
  • Undisclosed

    Bladder Cancer

    Discovery
    Mechanism:
    Proprietaty ADC technology

    Indication:
    Bladder Cancer

    Date commenced phase:
    Q3 2018

    Estimated filing:
    2021
  • Monoclonal Antibody

  • Undisclosed

    Anti-coagulation

    Preclinical
    Mechanism:
    Targetting blood coagulation factor

    Indication:
    anti-coagulation

    Date commenced phase:
    Q4 2018

    Estimated filing:
    December 2019
  • Undisclosed

    Gastric Cancer

    Preclinical
    Mechanism:
    Specific tumor antigen

    Indication:
    Gastric cancer

    Date commenced phase:
    Q4 2018

    Estimated filing:
    December 2019
  • Undisclosed

    Solid Tumor

    Discovery
    Mechanism:
    Block immuno-checkpoint

    Indication:
    Solid Tumor

    Estimated filing:
    2020
  • Undisclosed

    Solid Tumor

    Discovery
    Mechanism:
    Immuno-checkpoint agonist

    Indication:
    Solid Tumor

    Estimated filing:
    2020
  • Undisclosed

    NSCLC

    Discovery
    Mechanism:
    anti-inflammation factor

    Indication:
    NSCLC, Solid Tumor

    Date commenced phase:
    Q3 2018

    Estimated filing:
    2020
  • Undisclosed

    Asthma

    Discovery
    Indication:
    Asthma

    Date commenced phase:
    Q2 2018

    Estimated filing:
    2020
  • Bispecific Antibody

  • PD-L1/undisclosed

    Solid Tumor

    Preclinical
    Mechanism:
    Block immuno-checkpoint

    Indication:
    Solid Tumor

    Estimated filing:
    November 2019
  • Add: 8 Clarke Drive, Suite 4, Cranbury, New Jersey 08512
  • Email: Admin@kluspharma.com
  • Phone: (+ 001) 609-662-1913
  • Fax: (+ 001) 609-662-1918